Partnership / Collaboration · GCC · Announced 11 Nov 2026

Emirates Drug Establishment → Viatris

The Emirates Drug Establishment and Viatris signed an MoU to attract investment and localise pharmaceutical manufacturing in the UAE, covering local capabilities, supply-chain resilience and training of Emirati talent.

Parties: Emirates Drug Establishment (EDE) (United Arab Emirates) → Viatris (United States)

Value
Undisclosed
Territory
United Arab Emirates
Therapeutic area
Multi-therapy
Asset
Pharmaceutical localisation MoU
Announced
11 Nov 2026

Our analysis

Why this matters

The Emirates Drug Establishment (EDE) and Viatris signed a memorandum of understanding, announced on 11 November 2026, to boost investment and localise pharmaceutical manufacturing in the UAE. It was signed by EDE Director-General Dr Fatima Al Kaabi and Tamer Elsallab, Viatris's Head of GCC & Levant Cluster. The MoU covers local manufacturing capabilities, supply-chain resilience, training for Emirati talent, knowledge exchange and support for healthcare innovation. No values or timelines were given.

The MoU came with a concrete step: a separate Viatris–ADCAN Pharma agreement to localise manufacturing of selected Viatris products, signed in Al Kaabi's presence.

The full analysis is free to read with a work email on this page.

Source: GDN (TradeArabia news service)

More deals involving Emirates Drug Establishment or Viatris

Latest deals

All GCC deals → · All partnership / collaboration deals → · Browse all emerging-market pharma deals →